Moderna Therapeutics Inc (NASDAQ:MRNA) has revealed promising early-stage trial results for its combined Covid and influenza vaccine.
Interim phase I/II data suggests the dual jab matches the efficacy of taking separate shots for each virus.
Demonstrating a similar or even stronger immune response to existing flu vaccines, it also includes those tailored for the elderly by Sanofi.
Additionally, an immune response to the Sars-Cov-2 virus on par with Moderna's Covid-19 booster, Spikevax, was observed.
Announcing plans for a phase III trial later this year, Moderna's CEO, Stéphane Bancel, highlighted the potential advantages of such combination vaccines for healthcare systems and economies.
Stephen Hoge, Moderna's president, pointed out that healthcare systems could realise savings of $30 to $40 per vaccine in administration costs, including aspects like refrigeration and transportation, by opting for the combined shot.
Critics of the vaccine do exist, however. Questions arise about its convenience relative to administering two separate vaccines, and there are also concerns regarding potential side effects.
Pre-market, Moderna's stock was up 0.5% at $103.60.